Dendrite Announces Breakthrough Development Environment for Mobile Applications
August 08 2006 - 3:16PM
Business Wire
Dendrite International, Inc. (NASDAQ: DRTE), a leading provider of
pharmaceutical industry solutions, today announced a breakthrough,
flexible sales and marketing application environment for mobile
devices. This environment, called Project Mobility, is designed to
address the increased need for portability, convenience and
personalization afforded by the latest mobile devices with smart
phone technology. Dendrite's mobile environment will be used to
develop applications designed to increase communication between
every critical member in the pharmaceutical chain, from home office
to sales representatives, as well as from prescriber to patients.
With Dendrite's new application environment, companies will have
the same level of transparency as with today's sales force
effectiveness (SFE) applications, and will also benefit from the
freedom of a lightweight device, geo-centricity and real time
communication between home office and sales representative.
Longer-term, this breakthrough application environment will enable
the next generation of direct to patient health management
marketing programs. While Dendrite's first mobile application,
jForceWireless(TM), was launched in the second quarter of 2006 for
China and other emerging markets, the next applications will target
the United States domestic market. They will later be introduced in
Europe and Australia. Dendrite will develop all future applications
residing in this environment using Microsoft's Mobile PC platform.
All of the applications developed on this platform will be
device-agnostic using smart phone technology. "This environment is
designed to enable a broader range of life sciences companies to
benefit from Dendrite's robust solutions and deep domain
knowledge," said John Bailye, Dendrite's chairman and chief
executive officer. "Smaller pharmaceutical or medical device
companies that previously couldn't afford Dendrite's solutions now
can; larger companies will have the opportunity to augment their
existing Dendrite architecture as companion products; and all
companies that need to tackle the common prescriber to patient
communication issues will have the means by which to open a
dialog." The next application from this environment, an SFE
solution for small to medium sized pharmaceutical and medical
device companies, is currently being developed with feedback from
certain prospective customers. Dendrite currently anticipates
roll-out in the fourth quarter of 2006. Following this initial
application, the company expects to release several additional
solutions in 2007 and beyond. These solutions will be designed to
work together to address issues including patient adherence and
physician marketing, among others. About Dendrite Founded in 1986,
Dendrite International (NASDAQ: DRTE) enables sales, marketing,
clinical and compliance solutions for the global pharmaceutical
industry. The Company's clients are located in more than 50
countries and include the world's top 20 pharmaceutical companies.
For more information, please visit www.dendrite.com. Note: Dendrite
is a registered trademark of Dendrite International, Inc. This
document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect,"
"believe," "anticipate," "will," "intend," "plan," "target,"
"outlook," "guidance," and similar statements or variations. Such
forward-looking statements are based on our current expectations,
estimates, assumptions and projections and involve significant
risks and uncertainties, including risks which may result from our
dependence on the pharmaceutical industry; fluctuations in
quarterly revenues due to lengthy sales and implementation cycles
for certain of our solutions; our fixed expenses in relation to
fluctuating revenues and variations in customers' budget cycles;
dependence on certain major customers; changes in demand for our
products and services attributable to any weakness experienced in
the economy or mergers, acquisitions and consolidations in the
pharmaceutical industry; successful and timely development and
introduction of new products and versions; rapid technological
changes; increased competition; international operations;
integrating the entities we acquire; our ability to effectively
manage our growth; the protection of our proprietary technology;
our ability to compete in the Internet-related products and
services market; the continued demand for Internet-related products
and services; the ability of our third party vendors to respond to
technological change; our ability to maintain our relationships
with third-party vendors; less favorable than anticipated results
from strategic relationships; dependence of data solutions on
strategic relationships; events which may affect the U.S. and world
economies; and catastrophic events which could negatively affect
our information technology infrastructure. Other important factors
that should be reviewed and carefully considered are included in
the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to
reflect actual results, changes in assumptions or other changes
affecting such forward-looking statements.
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Dendrite International (MM) (NASDAQ): 0 recent articles
More Dendrite International, Inc. News Articles